

Matthew R Lammi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/59840/publications.pdf>

Version: 2024-02-01

36
papers

534
citations

623734

14
h-index

677142

22
g-index

37
all docs

37
docs citations

37
times ranked

745
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Handheld Ultrasound to Estimate Right Atrial Pressure in a Pulmonary Hypertension Clinic. <i>Annals of the American Thoracic Society</i> , 2022, 19, 179-185.	3.2	5
2	Implementation of a Longitudinal Critical Care Fellowship Ultrasound Curriculum. <i>ATS Scholar</i> , 2022, 3, 125-134.	1.3	2
3	HIV-associated Pulmonary Arterial Hypertension: A Report from the Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1121-1124.	5.6	10
4	Recommended Reading from the Louisiana State University Health Sciences Center-New Orleans Fellowship Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	5.6	1
5	Jugular venous ultrasound predicts outcomes in pulmonary hypertension outpatients. <i>European Respiratory Journal</i> , 2022, 59, 2102591.	6.7	0
6	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 229-237.	3.2	18
7	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 613-622.	3.2	27
8	Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study. <i>Respiratory Medicine</i> , 2021, 180, 106354.	2.9	2
9	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	17
10	Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089.	2.6	30
11	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
12	Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101695.	3.3	19
13	Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). <i>Pulmonary Circulation</i> , 2021, 11, 1-11.	1.7	3
14	An ode to the primal tonic of dance”congratulating the Life of Breath project. <i>Lancet Respiratory Medicine</i> , 2020, 8, e90-e91.	10.7	4
15	ATS Core Curriculum 2020. <i>Adult Pulmonary Medicine. ATS Scholar</i> , 2020, 1, 416-435.	1.3	0
16	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 945-953.	0.6	15
17	Use of red cell distribution width in a population at high risk for pulmonary hypertension. <i>Respiratory Medicine</i> , 2019, 150, 131-135.	2.9	11
18	Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers. <i>Respirology</i> , 2019, 24, 675-683.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Clinical Differences in COPD Patients with Variable Patterns of Hypoxemia. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 167-176.	0.7	2
20	Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: observations from the PHAROS cohort. Respirology, 2017, 22, 1386-1392.	2.3	7
21	Advances in Chronic Obstructive Pulmonary Disease Therapy: A Vascular-Targeted Approach. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1771912.	0.4	1
22	Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity. Mediators of Inflammation, 2016, 2016, 1-10.	3.0	11
23	Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L630-L638.	2.9	8
24	Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2016, 68, 740-748.	5.6	19
25	PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clinical Science, 2015, 129, 951-962.	4.3	35
26	PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function. Journal of Translational Medicine, 2015, 13, 225.	4.4	39
27	Response to Fluid Boluses in the Fluid and Catheter Treatment Trial. Chest, 2015, 148, 919-926.	0.8	43
28	DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4+ T-cell function without causing severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2015, 135, 425-440.	2.9	29
29	Air Current Applied to the Face Improves Exercise Performance in Patients with COPD. Lung, 2015, 193, 725-731.	3.3	26
30	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Current Respiratory Medicine Reviews, 2015, 11, 163-174.	0.2	29
31	PARP Inhibition Blocks Asthma Manifestation in a Chronic House Dust Mite (HDM) Asthma Model and Differentially Modulates Human CD4 + T cell Function. FASEB Journal, 2015, 29, 1027.5.	0.5	0
32	Determinants of CPAP Adherence in Hispanics with Obstructive Sleep Apnea. Sleep Disorders, 2014, 2014, 1-6.	1.4	15
33	Reduced dynamic hyperinflation after LVRS is associated with improved exercise tolerance. Respiratory Medicine, 2014, 108, 1491-1497.	2.9	4
34	Heterogeneity of Lung Volume Reduction Surgery Outcomes in Patients Selected by Use of Evidence-Based Criteria. Annals of Thoracic Surgery, 2013, 95, 1905-1911.	1.3	6
35	Increased oxygen pulse after lung volume reduction surgery is associated with reduced dynamic hyperinflation. European Respiratory Journal, 2012, 40, 837-843.	6.7	39
36	Pulmonary Tumor Embolism. Lung, 2010, 188, 441-443.	3.3	17